ARTICLE | Clinical News
CUDC-907 regulatory update
April 20, 2015 7:00 AM UTC
FDA granted Orphan Drug designation to CUDC-907 from Curis to treat diffuse large B cell lymphoma (DLBCL). Next half, Curis plans to begin a Phase II trial of the dual phosphoinositide 3-kinase (PI3K...